Home > Cardiology > AHA 2019 > New Frontiers in Lipid Therapy > ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients

ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients

Presented By
Prof. Frederick Raal, University of the Witwatersrand, South Africa
Conference
AHA 2019
Trial
Phase 3, ORION-9
The phase 3 ORION-9 trial data demonstrated that the novel lipid-lowering drug inclisiran halved low-density lipoprotein (LDL) levels in patients with familial hypercholesterolaemia (FH) [1]. Prof. Frederick Raal (University of the Witwatersrand, South Africa) presented the placebo-controlled 18-month follow-up data of 482 patients with diagnosed FH (half had genetic variants of the LDL receptor, 5% had apolipoprotein B variants, 1 patient had a PCSK9 gain-of-function variant, 7% had 2 different gene variants, and 24% had no detected gene variant). All subjects had LDL levels higher than 100 mg/dL (mean 150 mg/dL), and almost all were already taking maximum tolerated doses of statins (90% of patients; 80% were on high-intensity statin treatment) with or without ezetimibe (50% of patients). Participants were randomly assigned to receive subcutaneous injections of inclisiran 300 mg or placebo at d...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on